JP4459441B2 - ｓＰＬＡ２阻害剤エステル - Google Patents

ｓＰＬＡ２阻害剤エステル Download PDF

Info

Publication number
JP4459441B2
JP4459441B2 JP2000546777A JP2000546777A JP4459441B2 JP 4459441 B2 JP4459441 B2 JP 4459441B2 JP 2000546777 A JP2000546777 A JP 2000546777A JP 2000546777 A JP2000546777 A JP 2000546777A JP 4459441 B2 JP4459441 B2 JP 4459441B2
Authority
JP
Japan
Prior art keywords
methyl
phenylmethyl
indol
acetic acid
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000546777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513761A (ja
JP2002513761A5 (https=
Inventor
マイケル・ライル・デニー
ジョン・マイケル・モリン・ジュニア
ダニエル・ジョン・サル
ジェイソン・スコット・ソーヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JP2002513761A publication Critical patent/JP2002513761A/ja
Publication of JP2002513761A5 publication Critical patent/JP2002513761A5/ja
Application granted granted Critical
Publication of JP4459441B2 publication Critical patent/JP4459441B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000546777A 1998-05-01 1999-04-20 ｓＰＬＡ２阻害剤エステル Expired - Fee Related JP4459441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8387398P 1998-05-01 1998-05-01
US60/083,873 1998-05-01
PCT/US1999/008538 WO1999056752A1 (en) 1998-05-01 1999-04-20 sPLA2 INHIBITOR ESTER

Publications (3)

Publication Number Publication Date
JP2002513761A JP2002513761A (ja) 2002-05-14
JP2002513761A5 JP2002513761A5 (https=) 2006-06-22
JP4459441B2 true JP4459441B2 (ja) 2010-04-28

Family

ID=22181214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546777A Expired - Fee Related JP4459441B2 (ja) 1998-05-01 1999-04-20 ｓＰＬＡ２阻害剤エステル

Country Status (22)

Country Link
EP (1) EP1073440B1 (https=)
JP (1) JP4459441B2 (https=)
KR (1) KR20010071197A (https=)
CN (1) CN1303290A (https=)
AT (1) ATE280155T1 (https=)
AU (1) AU755901B2 (https=)
BR (1) BR9910149A (https=)
CA (1) CA2331036A1 (https=)
DE (1) DE69921314T2 (https=)
EA (1) EA003277B1 (https=)
ES (1) ES2230847T3 (https=)
HR (1) HRP20000738A2 (https=)
HU (1) HUP0201636A1 (https=)
ID (1) ID27812A (https=)
IL (1) IL139203A0 (https=)
NO (1) NO315940B1 (https=)
NZ (1) NZ507391A (https=)
PL (1) PL344571A1 (https=)
SK (1) SK16332000A3 (https=)
TR (1) TR200003198T2 (https=)
WO (1) WO1999056752A1 (https=)
ZA (1) ZA200005561B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101742907A (zh) * 2007-05-03 2010-06-16 安塞拉制药有限公司 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常
US20150335498A1 (en) * 2014-05-22 2015-11-26 The Procter & Gamble Company Heterogenous mass containing foam
US10729600B2 (en) 2015-06-30 2020-08-04 The Procter & Gamble Company Absorbent structure
CA3004313A1 (en) 2015-11-04 2017-05-11 The Procter & Gamble Company Absorbent structure
US11173078B2 (en) 2015-11-04 2021-11-16 The Procter & Gamble Company Absorbent structure
EP3370664B1 (en) 2015-11-04 2022-01-26 The Procter & Gamble Company Absorbent article comprising an absorbent structure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
BR9501404A (pt) * 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法

Also Published As

Publication number Publication date
ATE280155T1 (de) 2004-11-15
EA003277B1 (ru) 2003-04-24
JP2002513761A (ja) 2002-05-14
PL344571A1 (en) 2001-11-05
HRP20000738A2 (en) 2001-10-31
KR20010071197A (ko) 2001-07-28
BR9910149A (pt) 2001-10-02
ZA200005561B (en) 2002-01-10
IL139203A0 (en) 2001-11-25
CN1303290A (zh) 2001-07-11
CA2331036A1 (en) 1999-11-11
ID27812A (id) 2001-04-26
DE69921314T2 (de) 2006-02-09
WO1999056752A1 (en) 1999-11-11
NO315940B1 (no) 2003-11-17
EP1073440B1 (en) 2004-10-20
AU3652599A (en) 1999-11-23
SK16332000A3 (sk) 2001-06-11
EP1073440A4 (en) 2002-07-17
HUP0201636A1 (en) 2002-09-28
NO20005477D0 (no) 2000-10-31
AU755901B2 (en) 2003-01-02
NO20005477L (no) 2000-10-31
DE69921314D1 (de) 2004-11-25
NZ507391A (en) 2003-12-19
TR200003198T2 (tr) 2001-03-21
ES2230847T3 (es) 2005-05-01
EP1073440A1 (en) 2001-02-07
EA200001141A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
US5733923A (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
US5684034A (en) 1H-indole-3-acetamide sPLA2 inhibitors
US5641800A (en) 1H-indole-1-functional sPLA2 inhibitors
JP4459441B2 (ja) ｓＰＬＡ２阻害剤エステル
HU220221B (hu) 1H-Indol-3-ecetsav-hidrazid-származékok, a vegyületeket tartalmazó gyógyászati készítmények és eljárás előállításukra
JP2001520998A (ja) インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ
EP1202963B1 (en) Spla2 inhibitors
NO174198B (no) Analogifremgangsm}te for fremst.av den terapeutisk aktiveforbindelse 3-metoksy-4-(1-metyl-5-(2-metyl-4,4,4-trifluorbutylkarbamoyl)indol-3-ylmetyl)-N-(2-metylfenyl-sulfonyl)benzamid, eller et farmas!ytisk akseptabelt salt derav
US6274578B1 (en) sPLA2 inhibitor ester
US6274616B1 (en) N,N-diethylglycolamido ester prodrugs of indole sPLA2 inhibitors
US6706752B1 (en) sPLA2 inhibitors
JP4564669B2 (ja) インドールｓＰＬＡ２インヒビターのモルホリノ−Ｎ−エチルエステル誘導体
MXPA00010465A (en) sPLA2
CZ20004051A3 (cs) Ester jako inhibitor sPLA2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060419

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091104

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20091216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100210

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees